EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at
Experience Project.
Biogen Idec also announced that a Phase II study of BG-12 in patients with relapsing-remitting multiple sclerosis (MS) was initiated in November 2004. The study, being conducted in Europe, is a placebo-controlled, dose-ranging study designed to assess the efficacy and safety profile of BG-12. The primary endpoint of the study will be an MRI measurement of the amount of brain lesion activity at six months. Approximately 250 patients are expected to be enrolled in the study across 10 countries.
About BG-12
In October 2003, Biogen Idec licensed exclusive worldwide rights to develop and market BG-12 from Fumapharm AG, a privately held pharmaceutical company headquartered in Lucerne, Switzerland. BG-12 is an oral fumarate derivative with an immunomodulatory mechanism of action. Biogen Idec is evaluating BG-12 in a range of diseases, including psoriasis and MS.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
We encourage you to also visit our Multiple Sclerosis story and support community on Experience Project.
Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS,
on the premise that no one life experience-- like having MS-- defines a person. It now covers over 2 million life stories. Find and share yours!
Forum FAQ
Search
Usergroups
Profile
Log in to check your private messages
Log in
